AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

Psychosis affects one's physical, psychological, social, and existential health. Mental health recovery often involves a ...

Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

It hasn’t been an easy road for Joey Wilson. He says he’s dealt with the odds being against him since he was born prematurely ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Scientists have known for decades that the classic symptoms of schizophrenia, such as jumping to conclusions or difficulty ...

Researchers have developed a potential diagnostic tool for schizophrenia by observing how patients process conflicting information.

Researchers are using a groundbreaking technique to visualize a crucial molecule involved in neurotransmission in patients ...

A new study finds poor attention spans in childhood, plus certain genes, could play a role in raising the risk for psychosis, ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research Some people who took a new schizophrenia drug for a year ...